Zinc Alpha-2 Glycoprotein, Acylated Ghrelin, and Zinc Levels in Prediabetics

Basit Öğe Kaydı
dc.contributor.authorKurtulus, Eda merve
dc.contributor.authorKaris, Denizhan
dc.contributor.authorErcan, Alev meltem
dc.contributor.authorKonukoglu, Dildar
dc.date.accessioned2024-05-19T14:50:24Z
dc.date.available2024-05-19T14:50:24Z
dc.date.issued2024
dc.departmentİstinye Üniversitesien_US
dc.description.abstractBackground/Aim: Prediabetic stages of impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) exhibit differences in the sites of insulin resistance. Serum Zinc alpha-2 glycoprotein (ZAG), acylated ghrelin (AG), and zinc (Zn) levels can affect IFG, IGT, and diabetic glucose tolerance (DGT) differently. This study examined the importance of ZAG, AG, and serum Zn levels in prediabetic individuals with IFG, IGT, and DGT, compared to those with normal glucose levels. Patients and Methods: The study was conducted at Istanbul University Cerrahpasa-Cerrahpasa Faculty of Medicine. A total of n=151 volunteers were classified according to the WHO criteria for diabetes after undergoing an oral glucose tolerance test. Plasma and serum samples were measured by Inductively Coupled Plasma Optical Emission Spectroscopy, ELISA, and immunoassay. Results: Prediabetic conditions became more prominent with the decrease in ZAG levels. ZAG levels showed a negative correlation with acylated ghrelin and Homeostatic Model Assessment for assessing beta-cell function and insulin resistance. Zinc levels were significantly lower in DGT. Conclusion: ZAG levels have regulatory effects on insulin resistance and plasma glucose levels are mediated by zinc and acylated ghrelin.en_US
dc.description.sponsorshipResearch Fund of Istanbul University [29822]en_US
dc.description.sponsorshipThis work was supported by the Research Fund of Istanbul University. Project No. 29822.en_US
dc.identifier.doi10.21873/invivo.13530
dc.identifier.endpage981en_US
dc.identifier.issn0258-851X
dc.identifier.issn1791-7549
dc.identifier.issue2en_US
dc.identifier.pmid38418147en_US
dc.identifier.scopus2-s2.0-85186743072en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage975en_US
dc.identifier.urihttps://doi.org10.21873/invivo.13530
dc.identifier.urihttps://hdl.handle.net/20.500.12713/5699
dc.identifier.volume38en_US
dc.identifier.wosWOS:001179422300038en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherInt Inst Anticancer Researchen_US
dc.relation.ispartofIn Vivoen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240519_kaen_US
dc.subjectZinc Alpha 2 Glycoproteinen_US
dc.subjectAcylated Ghrelinen_US
dc.subjectZincen_US
dc.subjectOral Glucose Tolerance Testen_US
dc.subjectPrediabetesen_US
dc.titleZinc Alpha-2 Glycoprotein, Acylated Ghrelin, and Zinc Levels in Prediabeticsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu